CA-CEQUENCE-SECURITY
10.9.2019 06:02:08 CEST | Business Wire | Press release
Cequence Security, a provider of innovative application security solutions for today’s hyper-connected enterprises, today advanced its global expansion with the opening of its EMEA headquarters in Munich, Germany, and the appointments of accomplished cybersecurity executives David Curran as Vice President, EMEA, and James Sherlow as Director of Solutions Engineering. The Cequence Application Security Platform (ASP), which consolidates multiple security functions and breakthrough innovations to protect web, mobile, and API-based applications, will be showcased at three important events:
- OWASP Global AppSec Conference in Amsterdam, September 26-27, 2019, where Cequence Chief Product Officer and Co-Founder Ameya Talwalkar will be featured as a speaker.
- ISMG Cybersecurity Summit in London, October 22, 2019, where Ameya Talwalkar will also be featured as a speaker.
- Aviation ISAC Summit in Barcelona, Spain, the global event for aviation cybersecurity, October 30-November 1, 2019, where Cequence Chief Technology Officer and Co-Founder Shreyans Mehta will be featured as a speaker.
The award-winning Cequence platform, designed to support today’s cloud-native, container-based applications, was most recently chosen over numerous contenders as “Startup of the Year” in security software by Network Products Guide. The company and platform have amassed seven recognitions and awards from peers, customers, and analysts since the platform’s launch in November 2018.
Global leaders in the retail, financial, consumer services, and social media sectors rely on Cequence ASP and its integrated modules to protect their web, mobile, and API-based application tier with unprecedented effectiveness. The CQ botDefense Module thwarts malicious bot attacks by using the patented CQAI analytics engine to detect and defend against automated attacks that appear to be legitimate. The CQ appFirewall module similarly employs CQAI to provide non-stop security, even with continuous application updates and modifications to production apps at scale by DevOps teams. It prevents attacks targeting web, mobile, and API-based applications, and helps eliminate unwanted application traffic on enterprise networks.
“Hyperconnected organizations across the EMEA region are leading today’s digital economy, and their Internet-facing applications and APIs are increasingly the targets of advanced semantic and syntactic attacks,” said David Curran, Cequence Vice President, EMEA. “Cequence ASP provides unprecedented protection against business logic abuse such as Account Takeover, Fake Accounts, Content Scraping, Denial of Inventory, Application-level DDoS, API Abuse, Gift Card Fraud, Click Fraud, and Aggregator Abuse. It’s game-changing technology and I’m honored by the opportunity to help strengthen the security posture of these organizations.”
Additional Resources:
David Curran, Vice President, EMEA – bio
James Sherlow, Director of Solutions Engineering, EMEA – bio
Cequence Security
About Cequence Security
Cequence Security is a venture-backed cybersecurity software company founded in 2015 and based in Sunnyvale, CA. Its mission is to transform application security by consolidating multiple innovative security functions within an open, AI-powered software platform that protects customers web, mobile, and API-based applications – and supports today’s cloud-native, container-based application architectures. The company is led by industry veterans that previously held leadership positions at Palo Alto Networks and Symantec. Customers include F500 organizations across multiple vertical markets, and the solution has earned multiple industry accolades, including 2018 Gartner Cool Vendor. Learn more at www.cequence.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909006012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
